Endpoints News 生物医药· Ayisha Sharma·· 2026-10-20AI 评分42
Rapport Therapeutics 表示其从 J&J 获得许可的 AMPA 受体调节剂通过双相型躁狂症 II 期试验
Rapport says drug it licensed from J&J clears Phase 2 bipolar mania study
AI 导读
Rapport Therapeutics 称其从 J&J 获得许可的 investigational 口服 AMPA 受体调节剂在双相型躁狂症中期试验(Phase 2)中达到终点。
正文
Rapport Therapeutics said Tuesday its investigational oral drug that dials down the effect of AMPA receptors has cleared a mid-stage trial in bipolar mania, paving …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news